Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007
Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.
Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.